Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Metabolic disorders associated with the use of targeted cancer therapies

Kotecki, Nuriaa; Penel, Nicolasa; Awada, Ahmadb

doi: 10.1097/CCO.0000000000000176
INNOVATIVE EARLY CLINICAL TRIALS METHODOLOGY AND NEW THERAPEUTICS IN CANCER: Edited by Ahmad Awada
Buy

Purpose of review The everyday use of targeted therapies, whose mechanisms of action differ from the conventional cytotoxic agents, also causes the emergence of new toxicities as metabolic disorders about which little is known. We propose a systematic literature review of the incidence and physiopathology of targeted therapies-induced metabolic disorders and provide some management guidance.

Recent findings In recent decades, significant breakthroughs in molecular oncology and immunology have been made. The administration of targeted therapies and immunotherapy has been associated with metabolic toxicities such as endocrine disorders, dyslipidemia, induced diabetes, and electrolytic disorders. Current data show that metabolic disorders are becoming increasingly common, but rarely life threatening and often reversible with prompt therapeutic intervention.

Summary In the era of targeted therapies, medical oncologists should know the symptoms, carefully monitor patients for potential metabolic disorders, and manage these emerging side-effects with the help of endocrinologists and other medical specialists.

aDepartment of General Oncology, Center Oscar Lambret, Lille, France

bMedical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

Correspondence to Nuria Kotecki, MD, Centre Oscar Lambret 3, rue Frédéric Combemale, BP 307, Lille Cedex 59020, France. E-mail: n-kotecki@o-lambret.fr

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.